Symbol="ABUS"
AssetType="Common Stock"
Name="Arbutus Biopharma Corp"
Description="Arbutus Biopharma Corporation, a biopharmaceutical company, is dedicated to the discovery, development, and commercialization of a cure for patients with chronic hepatitis B virus (HBV) infection in the United States. The company is headquartered in Warminster, Pennsylvania."
CIK="1447028"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="100-8900 GLENLYON PARKWAY, BURNABY, BC, CA"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="338465000"
EBITDA="-73384000"
PERatio="None"
PEGRatio="0"
BookValue="0.807"
DividendPerShare="0"
DividendYield="0"
EPS="-0.46"
RevenuePerShareTTM="0.148"
ProfitMargin="0"
OperatingMarginTTM="-3.174"
ReturnOnAssetsTTM="-0.238"
ReturnOnEquityTTM="-0.507"
RevenueTTM="23535000"
GrossProfitTTM="-45389000"
DilutedEPSTTM="-0.46"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.673"
AnalystTargetPrice="5.4"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="11.68"
PriceToBookRatio="2.806"
EVToRevenue="7.67"
EVToEBITDA="-4.533"
Beta="2.102"
num_52WeekHigh="3.15"
num_52WeekLow="1.85"
num_50DayMovingAverage="2.17"
num_200DayMovingAverage="2.565"
SharesOutstanding="167557000"
DividendDate="None"
ExDividendDate="None"
symbol="ABUS"
open="2.02"
high="2.05"
low="2.00"
price="2.02"
volume="520474.00"
latest_trading_day="2023-08-30"
previous_close="2.03"
change="-0.01"
change_percent="-0.4926%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="89"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="11"
Volume_recent_avg="655025"
Change_recent_avg="0.01"
Delta_recent_avg="0.08"
Variance_recent_avg="0.04"
Change_ratio_recent_avg="-0.21"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="11"
Aroon_momentum_negative="89"
image_negative_thumbnail_id_1="1091"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0124.jpeg"
image_negative_thumbnail_id_2="1149"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0182.jpeg"
image_neutral_thumbnail_id_1="528"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0071.jpeg"
image_neutral_thumbnail_id_2="557"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0042.jpeg"
image_positive_thumbnail_id_1="678"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0030.jpeg"
image_positive_thumbnail_id_2="645"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0063.jpeg"
image_professor_thumbnail_id_1="1204"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0038.jpeg"
image_professor_thumbnail_id_2="1168"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0002.jpeg"
